Learn More
OBJECTIVE Axitinib is a potent and selective inhibitor of vascular endothelial growth factor receptors 1-3. This analysis compared efficacy and safety of axitinib plus gemcitabine in patients with(More)
In the double-blind, phase 3 PALOMA-3 study, palbociclib–fulvestrant significantly prolonged progression-free survival versus placebo–fulvestrant in patients with hormone receptor-positive (HR+),(More)
H. Mukai1, T. Yoshino2, S. Osera3, M. Sasaki1, C. Shimizu4, K. Yonemori5, M. Koudaira5, Y. Tanabe6, N. Matsuda7, N. Mizutani7, Y. Mori7, S. Hashigaki7, T. Nagasawa7, Y. Umeyama7, S. Randolph8, K.(More)